Diabetes Attitudes Wishes and Needs

Diabetes Attitudes Wishes and Needs (DAWN) 2 Study: A Multinational, Multi-stakeholder Survey Study of Psychosocial Issues in Diabetes and Patient-centred Diabetes Care

Sponsors

Lead Sponsor: Novo Nordisk A/S

Source Novo Nordisk A/S
Brief Summary

The study is conducted in Africa, Asia, Europe, Japan, North America and South America.

The multinational surveys will explore the experiences and unmet needs of people with diabetes, as well as those of family members of people with diabetes, and of healthcare professionals treating people with diabetes.

Overall Status Completed
Start Date March 2012
Completion Date September 2012
Primary Completion Date September 2012
Study Type Observational
Primary Outcome
Measure Time Frame
Self-reported health and Quality of Life (QoL) (measured by the study questionnaire) Day 1
Secondary Outcome
Measure Time Frame
Psychological well-being of people with diabetes and family members measured by the study questionnaire Day 1
Diabetes distress of people with diabetes and family members measured by the study questionnaire Day 1
Self-reported self-management of people with diabetes measured by the study questionnaire Day 1
Family support behaviours reported by people with diabetes and family members measured by the study questionnaire Day 1
Patient-centred diabetes care reported by people with diabetes and health care professionals measured by the study questionnaire Day 1
Enrollment 8985
Condition
Intervention

Intervention Type: Other

Intervention Name: No treatment given

Description: Three separate survey questionnaires, one for each of the three diabetes groups. Each questionnaire is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions and rating scales.

Eligibility

Sampling Method: Non-Probability Sample

Criteria:

Inclusion Criteria:

- Adults aged at least 18 years with diabetes (type 1 or type 2: not only during pregnancy)

- Adults aged at least 18 years involved in the daily care of an adult (18 years or older) with diabetes (type 1 or type 2)

- General practitioners who personally treat at least 5 adults (18 years or older) with diabetes per month and initiate oral medication

- Diabetes specialists (endocrinologists/diabetologists) who personally treat at least 50 adults (18 years or older) with diabetes per month and prescribe oral medication, insulin or other injectable diabetes medications

- Diabetes educators (diabetes nurses/dieticians/other non-physician healthcare professionals) providing care for at least 5 adults (18 years or older) with diabetes per month

- Participants must have access to the internet, either at home or at a location convenient to them, or be able to attend a face-to-face or telephone interview, to participate in the survey

- Provision of informed consent before the start of any study-related activities

Exclusion Criteria:

- Individuals aged below 18 years and/or diagnosed with diabetes less than 12 months ago

- Inability to understand and comply with written and verbal instructions

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
Global Clinical Registry (GCR, 1452) Study Director Novo Nordisk A/S
Location
Facility:
Novo Nordisk Investigational Site | Princeton, New Jersey, 08540, United States
Novo Nordisk Investigational Site | Algiers, 16035, Algeria
Novo Nordisk Investigational Site | Mississauga, L4W 4XI, Canada
Novo Nordisk Investigational Site | Beijing, Beijing, 100004, China
Novo Nordisk Investigational Site | Copenhagen S, 2300, Denmark
Novo Nordisk Investigational Site | Paris La défense cedex, 92932, France
Novo Nordisk Investigational Site | Mainz, 55127, Germany
Novo Nordisk Investigational Site | Bangalore, 560001, India
Novo Nordisk Investigational Site | Rome, 00144, Italy
Novo Nordisk Investigational Site | Tokyo, 1000005, Japan
Novo Nordisk Investigational Site | Mexico City, Mexico
Novo Nordisk Investigational Site | Alphen a/d Rijn, Netherlands
Novo Nordisk Investigational Site | Warszawa, PL-02-274, Poland
Novo Nordisk Investigational Site | Moscow, 119330, Russian Federation
Novo Nordisk Investigational Site | Madrid, 28033, Spain
Novo Nordisk Investigational Site | Istanbul, 34335, Turkey
Novo Nordisk Investigational Site | Crawley, RH11 9RT, United Kingdom
Location Countries

Algeria

Canada

China

Denmark

France

Germany

India

Italy

Japan

Mexico

Netherlands

Poland

Russian Federation

Spain

Turkey

United Kingdom

United States

Verification Date

January 2017

Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Arm Group

Label: People with Diabetes

Label: Family Members

Label: Healthcare Professionals

Acronym DAWN2
Study Design Info

Observational Model: Ecologic or Community

Time Perspective: Prospective

Source: ClinicalTrials.gov